Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2025 09:15 ET | Source: Lapix Therapeutics

LAPIX Therapeutics Doses First Patient-In Phase 1b Clinical Trial of LPX-TI641 for Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)

LPX-TI641 is a novel, orally bioavailable, potent small-molecule immunomodulator that restores immune tolerance by targeting multiple pathways implicated in autoimmune diseases.Topline Phase 1...
November 20, 2024 13:00 ET | Source: Lapix Therapeutics

LAPIX Therapeutics Announces Positive Topline Phase 1 Clinical Data Results with LPX-TI641 for the Treatment of Autoimmune Diseases

LPX-TI641 is an oral novel Treg-expanding T cell/transmembrane, immunoglobulin, and mucin (Tim)receptor agonist therapy in development for the treatment of autoimmune diseases such as rheumatoid...
February 07, 2024 09:00 ET | Source: Lapix Therapeutics

LAPIX Therapeutics Strengthens Board of Directors with Appointments of Pharmaceutical Industry Veterans Henry A. McKinnell, Ph.D., Anthony Gibney, and Francisco Leon, MD, Ph.D.

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for...
November 07, 2023 08:27 ET | Source: Lapix Therapeutics

LAPIX Therapeutics Inc. Announces First Subjects Dosed in its First-in-Human Clinical Study of its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis and other Autoimmune Conditions

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for...
September 18, 2023 09:00 ET | Source: Lapix Therapeutics

LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharmaceutical company focused on developing novel, orally bioavailable immune system restoration therapies for...
May 17, 2023 09:00 ET | Source: Lapix Therapeutics

LAPIX Therapeutics Inc. Announces the Issuance of U.S. Patent for LPX-TI641, Its First-in-Class, Orally Administered Tim3/4 Agonist for Treg Expansion to Treat Autoimmune Diseases

BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharma company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune...
January 26, 2023 09:00 ET | Source: Lapix Therapeutics

LAPIX Therapeutics Inc. Announces a Successful Conclusion of its Pre-IND Meeting Request with the U.S. FDA

BOSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a biopharma company focused on developing novel, orally bioavailable immune system restoration therapies for autoimmune...